Pds Biotechnology Corporation · NASDAQ:PDSB

Pds Biotechnology — Investor Presentation (October 2026)

28 slides from Pds Biotechnology's investor presentation, Oct 21, 2026

  1. Slide 1: Overview of PDS Biotech Drug Development Programs (Oncology)

    Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ: PDSB October 2026 Precision Designed Science for Immunotherapy

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corpo

  3. Slide 3: Clinically Validated Immunotherapies for Solid Tumors with High Unmet Need

    Clinically Validated Immunotherapies for Solid Tumors with High Unmet Need * Microsatellite stable (MSS) and/or mismatch repair-proficient (pMMR) disease. PDS Biotechnology NASDAQ: PDSB Two clinically advanced assets built on proprietary platforms that direct immune activity into the tumor, with dev

  4. Slide 4: Pipeline of Tumor-Targeted Immunotherapies

    Pipeline of Tumor-Targeted Immunotherapies ChemoRT = chemoradiotherapy; HAIP = hepatic artery infusion pump; ICI = immune checkpoint inhibitor. Therapy/Treatment Indication Phase 1 Phase 2 Phase 3 Partner PDS0301 Fused IL-12 antibody conjugate PDS0301 + Chemotherapy Advanced liver-associated cancers

  5. Slide 5: Overview of PDS0301

    & PDS Biotechnology Overview of PDS0301 (©2026 FOSBotecrralayy AlLRights Reserved!

  6. Slide 6: Proprietary IL-12 Immunocytokine: PDS0301 – Tumor Targeting Immunocytokine

    Proprietary IL-12 Immunocytokine: PDS0301 – Tumor Targeting Immunocytokine Tumor-targeted cytokine (IL-12) designed to accumulate within the tumor microenvironment (TME) with sustained presence in solid tumors5 Designed to address limitations of cytokine therapy and targets and accumulates in the TM

  7. Slide 7: PDS0301: Targets and Modifies the TME of Solid Tumors

    PDS0301: Targets and Modifies the TME of Solid Tumors to become Less Resistant to Treatment with Added T Cell & NK Cell Activation in the TME5-7 NK = Natural killer; TME = Tumor microenvironment The Solution PDS0301 fuses IL-12 to an antibody (NHS76) that seeks out dying tumor cells, delivering PDS0

  8. Slide 8: Phase Clinical Study of PDS0301 and Chemotherapy in mCRC with Liver Metastases

    Phase 2 Clinical Study of PDS0301 and Chemotherapy in mCRC with Liver Metastases

  9. Slide 9: Non-Randomized Phase Trial of PDS0301 + Chemotherapy in Colorectal Cancer with Liver Metastases

    Non-Randomized Phase 2 Trial of PDS0301+ Chemotherapy as 2L or 3L Therapy in Patients with MSS and pMMR* Colorectal Cancer with Liver Metastases Trial Evaluated Various Immune Responses as Potential Predictive Biomarkers * microsatellite stable (MSS) or mismatch repair-proficient (pMMR) disease Ther

  10. Slide 10: Chemotherapy + PDS0301 may Promote Durable Responses in Metastatic CRC

    Chemotherapy + PDS0301 may Promote Durable Responses in Metastatic CRC1,2 Encouraging Responses at 6 months Post Treatment; Monitoring of Durability Continues Sequentially performed study chemo +/- PDS0301 at the same National Cancer Institute clinical site; Chemotherapy = Floxuridine by Hepatic art

  11. Slide 11: 24-Month Survival Rate of Approximately 80%

    24-Month Survival Rate of Approximately 80%1,2 PDS0301 + Chemotherapy Appears to Provide Survival Benefit (Preliminary Results) *Sequentially performed studies at the same clinical site – Not randomized head-to-head. 11 Survival post-HAIP insertion (months) Probability of Survival 100 75 50 25 0 20

  12. Slide 12: Promising Results with PDS0301 in MSS/pMMR mCRC with Liver Metastases

    Promising Results with PDS0301 in MSS/pMMR Metastatic Colorectal Cancer (mCRC) with Liver Metastases NE= Not yet estimable – minimum follow up time of 13.1 months for PFS No randomized head-to-head study has been performed between PDS0301, chemotherapy or other agents. 12 Indication mCRC w/wo liver

  13. Slide 13: mCRC Program Provides Significant Value Creation Opportunity

    mCRC Program Provides Significant Value Creation Opportunity No head-to-head studies have been performed. Source: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market 13 71.4 80 >380 % Objective Response Rate1,2 <30% benchmark)* 24-month survival rate1,2 Dosed with PDS0301 i

  14. Slide 14: PDS0301 Value-Creating Milestones Over the Next 6-18 Months

    PDS0301 Value-Creating Milestones Over the Next 6-18 Months Demonstrate Potential Breadth in Solid Tumors Q4-2026/Q1-2027 Biochemically recurrent prostate cancer (Interim readout) Q1/Q2-2027 NCI-led - Colorectal cancer with liver metastases (Final data readout) Q2/Q3-2027 Metastatic castration resis

  15. Slide 15: PDS0301: Tumor-Targeted IL-12 with Clinical Proof of Concept in Solid Tumors

    PDS0301: Tumor-Targeted IL-12 with Clinical Proof of Concept in Solid Tumors Key Takeaways Targeted delivery to the tumor addresses limitations that have constrained IL-12 therapy. Fusion to the NHS76 antibody anchors PDS0301 in the tumor microenvironment, sustains presence in the tumor, and prevent

  16. Slide 16: Overview of PDS0101 in HPV16-Positive HNSCC

    Overview of PDS0101 in HPV16-Positive HNSCC

  17. Slide 17: HPV16+ Tumors Represent the Largest and Fastest Growing Type of HNSCC

    HPV16+ Tumors Represent the Largest and Fastest Growing Type of HNSCC HPV16+ HNSCC is Rapidly Increasing in US/EU Poor uptake of HPV vaccine15,16 Changing sexual behavior17 Unique pathophysiology of HPV1618 17 HPV16 HPV18 HPV 31/33/45/52/58 HPV 35/39/51/56/59/68 HPV-negative Annual Number of Orophar

  18. Slide 18: HPV16+ Patients Have No Targeted Therapies and Worse Clinical Outcomes

    HPV16+ Patients Have No Targeted Therapies and Worse Clinical Outcomes A targeted approach for HPV16+ patients in ICI-resistant HPV+ cancers represents a significant opportunity 18 Two head-to-head studies demonstrate that HPV16-positive patients have statistically worse survival compared to other p

  19. Slide 19: Proprietary Cancer Vaccine Platform: The Versamune Platform

    Proprietary Cancer Vaccine Platform: The Versamune® Platform – Mechanism for Targeted Immune Attack on Tumors Antigen = protein present in the cancer that can be recognized and attacked by the immune system. 19 Immunologically active R-enantiomer of1,2-dioleoyl-trimethyl-ammonium (R-DOTAP) R-DOTAP f

  20. Slide 20: PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors

    PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors21 20 CD4+helper T cell CD8+killer T cell HPV16 E6 & E7 Versamune®Activated CD8+Killer T Cell Versamune® +HPVmix (PDS0101) Dendritic Cell MHC class II MHC class I Tumor Lymph Node Targeted T CellsTrack to Tumor Subcutaneous Injecti

  21. Slide 21: Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors

    Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors VERSATILE-002: PDS0101 + Pembrolizumab in 1L HPV16+ R/M HNSCC PDS0101 5 doses: 1 mL Subcutaneous injection Q3W at Cycles 1, 2, 3, 4 & 12) + Pembrolizumab 200mg IV Q3W up to 35 Cycles (2 years) HPV16-positive R/M HNSCC

  22. Slide 22: PDS0101 + Pembrolizumab: mOS of 39.3 Months

    PDS0101 + Pembrolizumab: mOS of 39.3 Months3 12-18 Months mOS is Benchmark with Pembrolizumab and Pembrolizumab + Chemotherapy4 mOS = Median Overall Survival. No head-to-head studies have been performed. 22 Durable Survival: 11 Patients Surpassed 30 Months Time to Progression (months) Survival Fract

  23. Slide 23: PDS0101 + Pembrolizumab: Near or Complete Tumor Shrinkage in Difficult-to-Treat Patients

    PDS0101 + Pembrolizumab: Near or Complete Tumor Shrinkage in Difficult-to-Treat Patients3 63% of recruited patients into the study had low CPS 1-193 *Investigator assessment. 23 Results Confirmed disease control rate of 77.4%* ORR of 35.8%* 21% of patients tumor regression of 90-100%* CPS Group 1-19

  24. Slide 24: PDS0101 + Pembrolizumab: Well-Tolerated with a Low Incidence of Adverse Events

    PDS0101 + Pembrolizumab: Well-Tolerated with a Low Incidence of Adverse Events3 *Occurred 1 year after completing PDS0101 therapy while patient was still on pembrolizumab. 24 Treatment related adverse events (TRAEs) by Grade in ICI naïve and resistant patients n (%) Any Combination TRAE 76 (87.4) Gr

  25. Slide 25: PDS0101 + Pembrolizumab: Well-Positioned in 1L HPV16+ R/M HNSCC

    PDS0101 + Pembrolizumab:Well-Positioned in 1L HPV16+ R/M HNSCC PDS0101: Only Subcutaneous Combination Therapy in Late-stage Development for 1L HPV16+ HNSCC No head-to-head studies have been performed. 25 Combinations with pembrolizumab Median OS Not disclosed 21.3 months 22.6 months 39.3 months 95%

  26. Slide 26: Pipeline of Tumor-Targeted Immunotherapies

    Pipeline of Tumor-Targeted Immunotherapies ChemoRT = chemoradiotherapy; HAIP = hepatic artery infusion pump; ICI = immune checkpoint inhibitor. Therapy/Treatment Indication Phase 1 Phase 2 Phase 3 Partner PDS0301 Fused IL-12 antibody conjugate PDS0301 + Chemotherapy Advanced liver-associated cancers

  27. Slide 27: References

    References Eade AV et al, Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial; JCO Oncol Adv. 2026 Mar 10;3(1):e2500173 Eade AV et al, National Cancer Institute, Updated Interim Clinical Results

  28. Slide 28: References (cont'd)

    References (cont’d) Tabatabaeian H et al, Navigating therapeutic strategies: HPV classification in head and neck cancer, British Journal of Cancer. (2024) 131: 220-230 Landy R, et al JNCI: Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimul

PDS Biotechnology — Investor Presentation (October 2026) on 6ix